Capha Pharmaceuticals Inc. (OTCPK:FPSU.F) entered into a binding letter of intent to acquire Blockagram Inc. from Matt Warren for 0.000903 million on December 11, 2017. As on January 19, 2019, Capha Pharmaceuticals Inc. (OTCPK:FPSU.F) entered into the share exchange agreement to acquire Blockagram Inc. from Matt Warren. Capha will issue 7 million common shares for each Blockagram Share. Matt Warren will be owing approximately 8.59% of the issued and outstanding common shares of Capha. Upon completion of the transaction, the combined entity will continue to carry on the business of Blockagram and Blockagram will become the 100% wholly-owned subsidiary of Capha. As on January 19, 2018, the name changed from Capha Pharmaceuticals Inc. to Blockagram Corp. It has been agreed by both Blockagram and Capha that the proposed structure may be revised to accommodate tax considerations, accounting treatments and applicable legal and regulatory requirements. The Board of Directors of Capha following the transaction shall be comprised of five Directors and are expected to be Jeffrey Orridge, Daniel Kube, Roland Nimmo, Ronnie Strasser and James R. Brown. The executive management of Capha following the transaction is expected to be Jon James Atyeo as Chief Executive Officer, Roland Nimmo as Chief Financial Officer and Matt Warren as Chief Technology Officer. Letter of intent is expected to be superseded by a definitive agreement to be signed between the Blockagram and Capha on or before January 8, 2018. The transaction is subject to the satisfaction of customary closing conditions, including all regulatory approvals, including a change in the name of the Capha to Blockagram Corp. and the approval of the listing of Capha’s common shares on the Canadian Securities Exchange, the approval of the definitive agreement and the transaction by the Board Directors of each of Capha and Blockagram, the completion of satisfactory due diligence on each of Capha and Blockagram. As on January 19, 2019, the board of directors of both companies unanimously approved the terms which resulted in 7,000,000 shares of Capha Pharmaceuticals Inc. As on April 30, 2018 as the Capha and Blockagram have not been able to receive approval from security regulators within the required time frame. At the completion of the transaction, Blockagram intends to list its shares on the Canadian Securities Exchange. Capha Pharmaceuticals Inc. (OTCPK:FPSU.F) cancelled the acquisition of Blockagram Inc. from Matt Warren on April 30, 2018.